Avecho Biotechnology Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVEFF research report →
Companyavecho.com.au
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches.
- CEO
- Paul Gavin
- IPO
- 2018
- Employees
- 15
- HQ
- Clayton, VIC, AU
Price Chart
Valuation
- Market Cap
- $13.35M
- P/E
- -9.31
- P/S
- 28.76
- P/B
- 26.36
- EV/EBITDA
- -5.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.70%
- Op Margin
- -485.09%
- Net Margin
- -356.82%
- ROE
- -370.40%
- ROIC
- -64.50%
Growth & Income
- Revenue
- $1.24M · -4.38%
- Net Income
- $-4,414,887 · -41.41%
- EPS
- $0.00 · 230.00%
- Op Income
- $-6,001,941.4
- FCF YoY
- 127.78%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.18
- Avg Volume
- 162.00K
Get TickerSpark's AI analysis on AVEFF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AVEFF Coverage
We haven't published any research on AVEFF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVEFF Report →